Latest Blogs

Jun 20, 2019
Key cancer-related topics discussed at the AMA-HOD meeting included alcohol ingestion as a causation risk factor, appropriate guidelines for opioids in the cancer setting, and the use of de-identified patient information.
Jun 19, 2019
"We believe what mattered the most about #ASCO19 is that patients were part of the discussion," write Dr. Mark A. Lewis and Dr. Chadi Nabhan.
Jun 11, 2019
I am excited about the entire Breakthrough program, including a session I am leading on the impact of social media and telehealth on cancer care.
Jun 11, 2019
Real actions that promote women and under-represented groups in medicine are doable, starting today.
Subscribe to this column

Don S. Dizon, MD, FACP, FASCO

Don S. Dizon, MD, FACP, FASCO, is head of Women's Cancers at Lifespan Cancer Institute, director of Medical Oncology at Rhode Island Hospital, and a professor of medicine at The Warren Alpert Medical School of Brown University. Dr. Dizon serves as chair of ASCO's Social Media Working Group and is a past chair of the Cancer Communications Committee. In addition to his regular column on ASCOconnection.org, which has been honored with APEX awards in 2013 and 2014, he is a blogger for The Oncologist and a section editor of Gynecologic Oncology at UpToDate. Dr. Dizon is a member of the Journal of Clinical Oncology Editorial Board, and editor in chief of the ASCO Educational BookFollow Dr. Dizon on Twitter @drdonsdizon.

Mar 31, 2017
When a dying patient wanted more time at any cost, and our team collectively felt that a code would be inhumane, an ethics consultation helped provide clarity and support for our decision-making.
Mar 16, 2017
I tend to be cautious with the word cure, because sometimes that is the only thing that patients hear.
Feb 23, 2017
When the travel ban was announced, I worried for my patients and for my colleagues. I worried that medical care would be denied to international patients, including those who came to the U.S. for cancer care.
Feb 02, 2017
When it comes to many alternative therapies, the data is too sparse to inform discussions on benefits and/or risks, as my patient learned when her supplement use prevented her from continuing on a clinical trial.
Dec 27, 2016
With new therapies, fortunately, oncologists are now seeing patients over the span of years, and we get to know the person who is the patient beyond their illness. Many also bring along others on visit after visit, and we get to know each of them too.
Dec 14, 2016
As we move forward in oncology, my hope is that we will see miraculous recoveries more often, guided not by chance but by a better understanding of cancer biology. The promise of precision medicine remains a real one that I firmly believe in.

Pages